Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

GDUFA Research Impacting Generic Development, ANDA Approvals

22 Sep 2022

• By Derrick Gingery

drug discovery research — Bioequivalence method research has helped sponsors obtain ANDA approvals. • Source: Shutterstock

Related Content

Woodcock's Prophesy Comes True: US FDA ANDA Approvals Decline From Record Levels

19 Oct 2020

Growing Complex Generic Application Load May Force US FDA Staffing Changes

23 Nov 2021

US FDA's Generic Research Projects Appear To Be Opening Way For ANDAs

07 Jun 2018

US FDA's Generics Program Reaches 'Steady State' Milestone

07 Sep 2018

Generic Drug Bioequivalence Study Interruptions Not Just A Coronavirus Problem

11 May 2020

Some Generics May Get To Skip Fed Study Requirement If US FDA Research Pans Out

01 Jul 2021

Inhaler Changes For Environmental Reasons Worry Generic Sponsors, Prompt Call For FDA Research

20 May 2022

Additional Topics

United States Generic Drugs Research & Development Regulation Approvals BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.